 neoadjuv chemotherapi nonmetastat osteosarcoma extrem between septemb decemb patient osteosarcoma extrem second neoadjuv studi author institut patient cycl methotrex mtx cisplatinum cdp adriamycin adm surgeri patient good respond tumor necrosi adm mtx cdp poor respond tumor necrosi chemotherapi ifosfamid etoposid addit mtx adm cdp limb salvag possibl patient amput rotationplasti surgic margin adequ radic wide case inadequ margin intralesion averag follow-up period month rang patient diseas free pulmonari metastas patient local recurr first neoadjuv studi author institut mtx cdp percentag limb salvag good respond disease-fre surviv year second rizzoli neoadjuv studi system toxic chemotherapi superimpos retrospect analysi real dose intens patient correl intens chemotherapi prognosi